4
Changes in Ownership
HALOZYME THERAPEUTICS, INC. Filed Acc 0001528185-25-000004
PRESIDENT AND CEO sold 60,000 shares at an average $71.86 ($4,311,745)
- PRESIDENT AND CEO acquired 60,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Torley Helen · PRESIDENT AND CEO
Table I: Non-derivative
14 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +20,000 | $8.11 | $162,200 | 753,719 | D |
| 2025-10-01 | Sale : show line 2 in the form 10b5-1 | −11,705 | $75.11 | $879,151 | 742,014 | D |
| 2025-10-01 | Sale : show line 3 in the form 10b5-1 | −8,295 | $75.69 | $627,873 | 733,719 | D |
| 2025-10-02 | Exercise or conversion : show line 4 in the form 10b5-1 | +20,000 | $8.11 | $162,200 | 753,719 | D |
| 2025-10-02 | Sale : show line 5 in the form 10b5-1 | −6,600 | $70.51 | $465,359 | 747,119 | D |
| 2025-10-02 | Sale : show line 6 in the form 10b5-1 | −10,200 | $71.28 | $727,036 | 736,919 | D |
| 2025-10-02 | Sale : show line 7 in the form 10b5-1 | −2,400 | $72.07 | $172,956 | 734,519 | D |
| 2025-10-02 | Sale : show line 8 in the form 10b5-1 | −700 | $73.24 | $51,265 | 733,819 | D |
| Open-market sales · 60,000 sh · avg $71.86 · $4,311,745 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-01 | Exercise or conversion : show line 15 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $8.11 | $162,200 | 116,569 | D |
| 2025-10-02 | Exercise or conversion : show line 16 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $8.11 | $162,200 | 96,569 | D |
| 2025-10-03 | Exercise or conversion : show line 17 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $8.11 | $162,200 | 76,569 | D |
Loading xslF345X05/form4-10032025_091059.xml…